We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
LIVE INDIA: Effectiveness of Gla-100 in a Post hoc Pooled Analysis of FINE ASIA and GOAL Registries.
- Authors
Deshmukh, Vaishali; Chaudhury, Tirthankar; Chadha, Manoj; Chawla, Manoj; Mukherjee, Sagarika; Pitale, Shailesh; Basu, Debasis; Gadekar, Arvind; Menon, Shalini; Trivedi, Chirag; Salvi, Vaibhav; Ramakrishnan, Santosh; Goyal, Ghanshyam
- Abstract
Introduction: Real-world evidence on insulin glargine 100 U/ml (Gla-100) initiation in Indian type 2 diabetes mellitus (T2DM) individuals is limited. The present study aimed to evaluate the effectiveness of Gla-100 in insulin-naïve T2DM participants from India. Methods: This post hoc analysis includes real-world data of insulin-naïve Indian participants with T2DM who started Gla-100 treatment in two Asian registries: FINE ASIA and GOAL. Changes in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, insulin dose, and incidence of hypoglycemia from baseline to 6 months were assessed. Results: A total of 955 participants with T2DM were identified and analyzed. The mean [standard deviation (SD)] age and duration of diabetes were 54.7 (9.8) years and 9.8 (6.3) years, respectively. Mean HbA1c and FPG were significantly reduced after 6 months of Gla-100 treatment [− 2.07 (1.4) %; − 94.4 (65.2) mg/dl, respectively]. HbA1c targets of < 7.0% and < 7.5% were achieved by 292 (30.6%) and 589 (61.7%) study participants, respectively. The overall incidence of hypoglycemia was low (n = 52; 5.4%); only two participants (0.2%) reported severe hypoglycemia. Insulin was titrated with a mean (SD) increment of 2.5 (5.6) U/day after 6 months, leading to a mean Gla-100 dose of 18.2 (8.9) U/day. Mean body weight remained unchanged from baseline to 6 months (− 0.1 kg). Conclusion: In routine clinical practice, Gla-100 significantly improved glycemic parameters after 6 months of treatment with a low risk of hypoglycemia and no weight change in participants with T2DM.
- Subjects
INDIA; ASIA; TYPE 2 diabetes; GLYCOSYLATED hemoglobin; BLOOD sugar; HYPOGLYCEMIA
- Publication
Diabetes Therapy, 2023, Vol 14, Issue 12, p2075
- ISSN
1869-6953
- Publication type
Article
- DOI
10.1007/s13300-023-01469-3